Latest Content

FDA Grants Two Designations to TT125-802 for Mutated Lung Cancers

September 3rd 2025, 9:00pm

By Ryan Scott

Article

The FDA granted two fast track designations to TT125-802, an investigational therapy, for the treatment of advanced/metastatic non-small cell lung cancer.

Targeted and Combination Therapies Reshape Leukemia Care

September 3rd 2025, 8:00pm

By Dr. Firas El Chaer

Video

Advances in leukemia treatment now include targeted drugs, lighter chemotherapy and combination regimens that improve tolerance and reduce resistance.

Prostate Cancer Awareness Month: Focus on Detection and Treatment

September 3rd 2025, 7:00pm

By Dr. David A. Taub

Article

Dr. David A. Taub discussed why Prostate Cancer Awareness Month marks a time to highlight early detection and evolving treatment in an interview with CURE.

Pushing My Reset Button: Finding Balance and Healing Through Cancer

September 3rd 2025, 5:00pm

By Ronald Chin

Article

Through exercise, meditation, and gratitude, I reset my mind and body, finding peace and strength in life after my cancer diagnosis.

How Leukemia Treatment Has Evolved in Recent Years

September 3rd 2025, 4:00pm

By Alex Biese

Article

In observation of Leukemia Awareness Month in September, CURE spoke with an expert about basics of the disease.

Haystack MRD Test Gets Breakthrough Designation in Stage 2 Colorectal Cancer

September 3rd 2025, 3:00pm

By Spencer Feldman

Article

The FDA granted breakthrough device designation to the Haystack MRD test, which uses ctDNA to detect residual or recurrent stage 2 colorectal cancer.

How Patients With Kidney Cancer Can Advocate for Themselves in Care

September 3rd 2025, 1:00pm

By Bryan Lewis

Video

Patients can best advocate for themselves by asking questions and remembering they have the right to be active participants in their care.

Early Prostate Cancer Detection: Why PSA Screening Matters

September 2nd 2025, 9:00pm

By Dr. Paul Gellhaus

Article

Dr. Paul Gellhaus says PSA testing and modern biopsy methods ease fears and reassure patients, making early prostate cancer detection safe and valuable.

An Expert Discusses Ovarian Cancer Basics, From Staging to Treatment

September 2nd 2025, 8:00pm

By Alex Biese

Article

CURE spoke with Dr. Ryan Kahn of Miami Cancer Institute for Ovarian Cancer Awareness Month.

Every Oncologic FDA Approval Throughout August 2025

September 2nd 2025, 7:00pm

By Ryan Scott

Article

In August 2025, the FDA approved various anti-cancer treatments across a range of disease types, such as colorectal, lung cancer and brain cancer.

What Does ‘Standing Up to Cancer’ Mean to You?

September 2nd 2025, 5:00pm

By Robin Zimmerman

Article

For me, standing up to cancer means honoring my wife’s melanoma journey by raising awareness, supporting early detection and research.

FDA Approved Camcevi ETM New Drug Application for Prostate Cancer

September 2nd 2025, 4:00pm

By Alex Biese

Article

The FDA has approved the NDA for Camcevi ETM for the treatment of advanced prostate cancer.

FDA Approves Bildyos and Bilprevda Biosimilars for Bone Cancer Care

September 2nd 2025, 3:00pm

By Spencer Feldman

Article

The FDA approved Bildyos and Bilprevda as biosimilars to Prolia and Xgeva, expanding bone care options for osteoporosis, cancer and more.

Expert Discusses Treatment Advances During Ovarian Cancer Awareness Month

September 2nd 2025, 1:00pm

By Dr. Ryan Kahn

Video

Elahere, validated in a phase 3 trial, is FDA-approved and offers the first major advancement for platinum-resistant ovarian cancer in decades.

Expert Outlines Prostate Cancer Treatment Options for Awareness Month

September 1st 2025, 3:00pm

By Dr. David A. Taub

Video

In an interview, Dr. David A. Taub highlighted Prostate Cancer Awareness Month by outlining current treatment options for patients with prostate cancer.